Abstract��OBJECTIVE To evaluatethe rationality and normativity of the contents of thepackage insert of dexamethasoneinjectionrelated to medicationsafety, thus to facilitate the rational use of dexamethasoneinjection. METHODS The contentsof dosage and administration, adverse drug reaction, and precautionsin the package insert of dexamethasoneinjectionwere reviewed, and the rationality and normativity of the contents were discussed according tothe published papers and the clinical medication practice in our hospital. RESULTS The contents of the package insert of dexamethasone injectionwere simple, some of the expressionswereambiguousor not standard. Dexamethasone is a long-acting glucocorticoid drug, which has a great influence on human glucose metabolism, while the effect of water and sodium retention is weak. Using 5% glucose injection as the solvent of dexamethasone as stated in the package insertmay exacerbate hyperglycemia, and 0.9% sodium chloride injection should generally be used as the dilution solvent. Besides, when the stock solution is directly injected intravenously, the adverse reactionsof gastrointestinal tract and nervous system may be aggravated. Additionally, there was no precaution statement in the package insert that dexamethasonemay induce hypokalemia in a minority of patients even at single low dose. CONCLUSION Package insertsof drugs are legal instruments and the most important evidence to guide the rational use of medications. Therefore, it is suggested that the package insert of dexamethasoneinjection should be further improved and revised, which will be of great significance in the implementation of clinical guidelines of glucocorticoids applicationand the rational use of glucocorticoids.
˾�̸�. ��������ע��Һ�ٴ�Ӧ�ð�ȫ�Է�������[J]. �й�ҩѧ��־, 2016, 51(22): 1972-1975.
SI Ji-gang. Rationality and Normativity of the Package Insert of Dexamethasone Injection Related to Medication Safety. Chinese Pharmaceutical Journal, 2016, 51(22): 1972-1975.
LIU Y, ZHANG G M, ZHANG Y H. Analysis on the clinical application of glucocorticoids in our hospital[J]. Chin Pharm J (�й�ҩѧ��־), 2014, 49(3):250-252.
[2]
HE F, WANG X C, WANG X B, et al. Retrospective analysis of the clinical rational drug use refer to NCCN antiemetic guideline[J]. Chin Pharm J (�й�ҩѧ��־), 2015, 50(19):1731-1734.
[3]
Medical Administration Department of National Health Ministry issued the document (2011)23. Clinical guidelines of glucocorticoids application[S]. 2011-02-16.http://www.nhfpc.gov.cn/yzygj/s3585u/201102/91566d6e98df4916b8aa018e37605603.shtml
[4]
LI L J, CAO Y H. Study on the rate of intravenous injection of dexamethasone in children[J]. Guide China Med (�й�ҽҩָ��), 2012, 10(21):589-590.
[5]
LI Q. Study on three methods of dexamethasone administered by intravenous injection[J]. Chin Commun Doct (�й�����ҽʦ), 2010, 12(14):215.
[6]
WANG Z J, ZHAO S, DENG A P, et al. Blood glucose change characteristics and countermeasures of glucocorticoid therapy for patients with idiopathic thrombocytopenic purpura[J].J China Pharm(�й�ҩ��), 2011, 22(14):1304-1306.
[7]
YAN F, SUN Y. Effect of dexamethasone on blood glucose in patients with gestational diabetes mellitus[J]. Chin Clin Dr (�й��ٴ�ҽ����־) , 2015, 43(7):57-60.
[8]
ABDELMANNAN D, TAHBOUB R,GENUTH S,et al. Effect of dexamethasone on oral glucose tolerance in healthy adults [J]. Endoc Pract, 2010, 16(5):770-777.
[9]
WANG Y Y, GUO D H, LIU G Y, et al. Analysis of dexamethasone-induced hiccup[J]. Chin J Drug Appl Monit (�й�ҩ��Ӧ������) , 2011, 8(2):105-107.
[10]
DU J X, MA M L. Adverse drug reactions induced by dexamethasone:literature analysis of 158 cases[J]. J China Pharm (�й�ҩ��), 2011, 22(48):4588-4590.
[11]
TONG J. Clinical analysis of 13 cases of hypokalemia induced by intramuscular injection of small dose dexamethasone[J]. J Med Theory Pract (ҽѧ������ʵ��), 2014, 27(16):2172-2173.
[12]
LUO S. Report of four cases of low potassium induced by intravenous dexamethasone[J]. China Mod Doct (�й��ִ�ҽ��), 2010, 48(1):104.
[13]
ZHANG W S. A report of two cases of low potassium paralysis induced by intravenous dexamethasone [J]. Public Med Forum Mag (����ҽѧ��̳), 2015, 19(31):1.
[14]
MA R F. Clinical analysis of 20 cases of low potassium periodic paralysis induced by glucose and dexamethasone[J]. Chin Postgrad Med (�й�ҽʦ������־), 2013, 36(4):67-68.
[15]
LIU J F, LI L W, QIU X G. Analysis of the hypokalemia complication of dexamethasone used for hyperthyroidism preoperative preparation[J]. Intern J Surg (�������ѧ��־), 2013, 40(11):755-757.
[16]
JING Q B, YU X J, LI Y F, et al. A case of low potassium induced by combination of dexamethasone and dexamethasone[J]. J North Pharm (����ҩѧ), 2014, 11(7):25.
[17]
NI W Y, XIAO D K, WANG J F. A case of death of low potassium in combination with lincomycin and dexamethasone [J]. Health Res (�����о�), 2010, 30(3):207-209.
[18]
MYLES T D. Steroids-plenty of benefits, but not without risk[J]. Obstet Gynecol,2011,117(2 Pt 2):429-430.
[19]
XIA D S. Analysis of the situation and tendency on official documents requiring manufacturers to revise the package inserts issued by chinese drug regulatory authority in the late 8 years[J]. J China Pharm(�й�ҩ��), 2014, 25(4):3853-3856.
[20]
LIU M H, WU Q Q. Investigation of the status quo of package inserts and analysis of related risk in our hospital[J]. J China Pharm (�й�ҩ��), 2012, 23(17):1619-1621.
[21]
LIU M H, LI G J, WU Q Q. Study on evaluation of drug performance by "modification dates" in drug instructions[J].Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2015, 35(14):1335-1339.
2016, Vol. 51 
